YOKNEAM, Israel, Oct. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani, President of North America effective September 30, 2024. His departure follows that of Dr. Spero Theodorou, Chief Medical Officer, and Dan Wilson, VP of Sales USA.
In addition to the departure of the three executives from InMode's North American operations, over the last few months, InMode has changed the management teams in three of its subsidiaries in Europe: InMode UK, InMode Iberia and InMode France.
These changes come as part of InMode's ongoing effort to establish an optimal company structure that aligns with its global expansion and penetration into new business verticals. As the Company continues to expand into the wellness sector, it has become clear that a reorganization is necessary to ensure that InMode has the right structure, and skill sets in place to support future goals.
InMode has a full pipeline of new platforms, with over a dozen already in the market and more on the horizon. To manage this growth effectively, the role of President of North America will be divided into separate roles, each providing the focus needed for the Company's evolving business landscape.
Moshe Mizrahy, InMode's CEO, said, "This new structure is designed to enhance operational efficiency of our North American operations. This reorganization marks an important step in InMode's evolution as a global company and demonstrates our commitment to building a robust infrastructure for future growth. I will be working closely with the executive team in North America to guide this transition.
"We thank Shakil, Dr. Theodorou, and Dan, and wish them the best of luck in their future endeavors. We look forward to the exciting opportunities ahead," concluded Moshe Mizrahy.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
Last Trade: | US$14.59 |
Daily Change: | -0.35 -2.34 |
Daily Volume: | 195,971 |
Market Cap: | US$922.230M |
September 02, 2025 July 30, 2025 April 28, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load